Shares of Poseida Therapeutics Inc. (NASDAQ:PSTX) closed at $4.51, up $2.08, or 85%, as a result of the collaboration and licensing deal with Roche Holding AG that brings $110 million up front as well as the same amount in near-term milestone payments described by CEO Mark Gergen as “highly achievable,” and the arrangement could be worth as much as $6 billion if goals farther down the road are met. Read More
Genentech Inc. is paying Kiniksa Pharmaceuticals Ltd. $100 million in up-front and near-term payments for the development and commercialization rights to vixarelimab, a fully human monoclonal antibody. Kiniksa also could receive up to approximately $600 million in certain clinical, regulatory and sales-based milestones, as well as royalties on annual net sales. Read More
Researchers are closer to better diagnosing and treating age-related macular degeneration (AMD) after discovering new genetic signatures of the disease by reprogramming stem cells to generate high-resolution disease models. Read More
A rash of recent announcements in the diabetes market speak to the brisk pace of developments and keen competition in the field. Dexcom Inc. reported good news in the U.K. and Europe, offset by delays in the U.S., while Insulet Corp. gave investors assurance that it was moving full speed ahead in the release of its Omnipod artificial pancreas system. On the pharma side, Arecor Therapeutics plc signed a contingent agreement to acquire Tetris Pharma Ltd. and commercialize Ogluo in the U.K., E.U. and other countries. Read More
No one denies that fewer new drugs will be a consequence of the Medicare drug pricing provisions the Democrats are trying to push through the U.S. Congress ahead of the midterm election campaign season. Read More
If anti-aging drugs are to become widely available and adopted, especially in the U.S., they have some serious hurdles to overcome. And those hurdles aren’t all in the lab or clinic. With classes of anti-aging drugs already in the pipeline, “the biggest hurdle is FDA approval. Then reimbursement,” said George Kuchel, a professor and director of the UConn Center on Aging at the University of Connecticut. Read the final installment of BioWorld’s multipart series on extending the human lifespan. Read More
In Extending the human lifespan, a BioWorld special report, the team examined the latest science, the key biological drivers that can be targeted pharmacologically and the companies developing potential “Fountain of Youth” candidate drugs. In this episode of the BioWorld Insider Podcast, the team discussed the report’s highlights and key takeaways.
Please take a few minutes to fill out this short survey to help us provide you with the best possible source of news. Customer feedback is critical so that we can make BioWorld a valuable component of your daily workflow. We want to continue to evolve to serve you. The survey should take just 5 minutes. You can click through to the questions here. Read More
New hires and promotions in the biopharma industry, including: Alumis, Amneal, Arbor, Carsgen, Evofem, Nurix, Pharmaessentia, Profoundbio, Rallybio, Tevard. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alzecure, Avalo, Axcella, Bio-Thera, Caladrius, Eliem, Halozyme, Ocuterra, Orca, Satsuma, Structure, Tavanta. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Biontech, Calidi, Cellectis, Pfizer, Takeda. Read More
